Targeting NF-κB for colorectal cancer

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 6, 2010, Pages 593-601

  Sakamoto, Kei ^a   Maeda, Shin ^b  

^a INSTITUTE FOR ADULT DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Colorectal cancer; Inflammation; Molecular target therapy; NF B

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; I KAPPA B KINASE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; CANCER INVASION; CELL DEATH; CELL PROLIFERATION; COLORECTAL CANCER; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENTERITIS; GENE ACTIVATION; GENE ACTIVITY; GENE FUNCTION; GENE MUTATION; GENE TARGETING; GROWTH INHIBITION; HUMAN; METASTASIS; NONHUMAN; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH; ANIMAL; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 77952267296     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728221003769903     Document Type: Review

References (80)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4) : 225-49
2. Chu QS, Hammond LA, Schwartz G, et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 2004; 10 (15) : 4913-21
3. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22 (2) : 229-37
4. Arsene D, Galais MP, Bouhier-Leporrier K, Reimund JM. Recent developments in colorectal cancer treatment by monoclonal antibodies. Expert Opin Biol Ther 2006; 6 (11) : 1175-92
5. Fakih M. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? Expert Rev Anticancer Ther 2008; 8 (9) : 1471-80
6. Prat A, Casado E, Cortes J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007; 13 (44) : 5857-66
7. Rodriguez J, Zarate R, Bandres E, et al. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007; 13 (44) : 5867-76
8. Kamata H, Honda S, Maeda S, et al. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120 (5) : 649-61
9. Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci 2008; 99 (5) : 836-42
10. Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118 (6) : 671-4
11. Karin M, Cao Y, Greten FR, Li ZW. NF-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2 (4) : 301-10
12. Ghosh S, Karin M. Missing pieces in the NF-kB puzzle. Cell 2002; 109 (Suppl) : S81-96
13. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54 (11) : 1573-8
14. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48 (4) : 526-35
15. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91 (4) : 854-62
16. Atreya I, Atreya R, Neurath MF. NF-kB in inflammatory bowel disease. J Intern Med 2008; 263 (6) : 591-6
17. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kB abrogates established experimental colitis in mice. Nat Med 1996; 2 (9) : 998-1004
18. Rogler G, Brand K, Vogl D, et al. Nuclear factor kB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115 (2) : 357-69
19. Neurath MF, Fuss I, Schurmann G, et al. Cytokine gene transcription by NF-kB family members in patients with inflammatory bowel disease. Ann NY Acad Sci 1998;859:149-59
20. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347 (6) : 417-29
21. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 (Suppl 2) : 1-5
22. Yan F, Polk DB. Aminosalicylic acid inhibits IkB kinase alpha phosphorylation of IkBalpha in mouse intestinal epithelial cells. J Biol Chem 1999; 274 (51) : 36631-6
23. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118 (3) : 285-96
24. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21 (4) : 491-501
25. Shibata W, Maeda S, Hikiba Y, et al. Cutting edge: the IkB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 2007; 179 (5) : 2681-5
26. Hayakawa Y, Maeda S, Nakagawa H, et al. Effectiveness of IkB kinase inhibitors in murine colitis-associated tumorigenesis. J Gastroenterol 2009; 44 (9) : 935-43
27. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003; 3 (9) : 695-701
28. Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 2000; 190 (4) : 412-6
29. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 (1) : 57-70
30. Joyce D, Albanese C, Steer J, et al. NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001; 12 (1) : 73-90
31. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002; 13 (4-5) : 413-21
32. Goldring MB, Otero M, Tsuchimochi K, et al. Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis 2008; 67 (Suppl 3) : 75-82
33. Chen F, Lu Y, Castranova V, et al. Loss of Ikkbeta promotes migration and proliferation of mouse embryo fibroblast cells. J Biol Chem 2006; 281 (48) : 37142-9
34. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005; 115 (10) : 2625-32
35. De Smaele E, Zazzeroni F, Papa S, et al. Induction of gadd45beta by NF-κB downregulates pro-apoptotic JNK signalling. Nature 2001; 414 (6861) : 308-13
36. Muerkoster S, Arlt A, Sipos B, et al. Increased expression of the E3-ubiquitin ligase receptor subunit beta TRCP1 relates to constitutive nuclear factor-kB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 2005; 65 (4) : 1316-24
37. Cheng Q, Lee HH, Li Y, et al. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition. Oncogene 2000; 19 (42) : 4936-40
38. Kunnumakkara AB, Guha S, Krishnan S, et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products. Cancer Res 2007; 67 (8) : 3853-61
39. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2 (3) : 161-74
40. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28 (1-2) : 15-33
41. Huber MA, Azoitei N, Baumann B, et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114 (4) : 569-81
42. Wu Y, Deng J, Rychahou PG, et al. Stabilization of snail by NF-κB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009; 15 (5) : 416-28
43. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457 (7225) : 102-6
44. Maeda S, Hikiba Y, Sakamoto K, et al. Ik B kinasebeta/nuclear factor-kB activation controls the development of liver metastasis by way of interleukin-6 expression. Hepatology 2009; 50 (6) : 1851-60
45. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23) : 2335-42
46. Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72 (11) : 1605-21
47. Sakamoto K, Maeda S, Hikiba Y, et al. Constitutive NF-κB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 2009; 15 (7) : 2248-58
48. Bates RC, DeLeo MJ III, Mercurio AM. The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res 2004; 299 (2) : 315-24
49. Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 2006; 66 (6) : 3071-7
50. Wang D, Richmond A. Nuclear factor-kB activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem 2001; 276 (5) : 3650-9
51. Ma J, Wang Q, Fei T, et al. MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007; 109 (3) : 987-94
52. Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007; 26 (3-4) : 453-67
53. Scapini P, Morini M, Tecchio C, et al. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 2004; 172 (8) : 5034-40
54. Voboril R, Weberova-Voborilova J. Constitutive NF-kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis. Neoplasma 2006; 53 (6) : 518-23
55. Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-kB is upregulated in colorectal cancer. Surgery 2001; 130 (2) : 363-9
56. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008; 11 (4-5) : 164-79
57. Williams S, Pettaway C, Song R, et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003; 2 (9) : 835-43
58. Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66 (7) : 3773-81
59. Zhu H, Zhang L, Dong F, et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005; 24 (31) : 4993-9
60. Caponigro F, Lacombe D, Twelves C, et al. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Eur J Cancer 2009; 45 (1) : 48-55
61. San Miguel J, Blade J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006; 11 (1) : 51-61 (Pubitemid 43152686)
62. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009; 374 (9686) : 324-39
63. Jin SH, Kim TI, Han DS, et al. Thalidomide suppresses the interleukin 1beta-induced NFkB signaling pathway in colon cancer cells. Ann NY Acad Sci 2002;973:414-8
64. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113 (9) : 1875-91
65. Yu J, Qian H, Li Y, et al. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. Gynecol Oncol 2007; 106 (2) : 400-6
66. Subbarayan PR, Lima M, Ardalan B. Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 2007; 46 (4) : 557-61
67. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene 1999; 18 (49) : 6896-909
68. Saklatvala J. Glucocorticoids: do we know how they work? Arthritis Res 2002; 4 (3) : 146-50
69. Almawi WY, Melemedjian OK. Negative regulation of nuclear factor-kB activation and function by glucocorticoids. J Mol Endocrinol 2002; 28 (2) : 69-78
70. Kemeny N, Capanu M, D'Angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 2009; 20 (7) : 1236-41
71. Sakimura K, Omori T, Iwashita E, et al. Clinical response is associated with elevated plasma interleukin-1 receptor antagonist during selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006; 51 (9) : 1525-31
72. Graziano F, Ruzzo A, Canestrari E, et al. Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Pharmacogenomics J 2009; 9 (1) : 78-84
73. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3 (1) : 17-26
74. You M, Ku PT, Hrdlickova R, Bose HR Jr. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol Cell Biol 1997; 17 (12) : 7328-41
75. Stehlik C, de Martin R, Kumabashiri I, et al. Nuclear factor (NF)-kB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 1998; 188 (1) : 211-6
76. Stehlik C, de Martin R, Binder BR, Lipp J. Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NF-κB. Biochem Biophys Res Commun 1998; 243 (3) : 827-32
77. Roy N, Deveraux QL, Takahashi R, et al. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997; 16 (23) : 6914-25
78. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131 (4) : 669-81
79. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 1997;385:540-4
80. Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-κB activation pathways by NF-B-inducing kinase. Immunity 2004; 21 (4) : 477-89